Novo Nordisk said Tuesday it will slash the list prices of several of its popular pre-filled insulin pens and vials by up to 75%, becoming the latest drugmaker to reduce the cost of the critical ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

California Gov. Gavin Newsom said the state will begin making its own insulin to help lower the cost of the diabetes medication. WSJ explains how insulin got so expensive in the U.S. and explores ...

A recent Scientific Reports study explored the association between dietary insulin index (DII) and dietary insulin load (DIL) with metabolic healthy (MH) status and the serum levels of brain-derived ...

Novo Nordisk will lower the U.S. list price of some of its insulin products by up to 75%, the Danish drugmaker said Tuesday. The change — which will take effect on Jan. 1, 2024 — follows a similar ...

Following the lead of its rivals, Sanofi will cut the price of its most widely prescribed insulin in the U.S. by 78% and also place a $35 cap on out-of-pocket costs for commercially insured patients ...

A recent study found that the homeostasis model assessment insulin resistance (HOMA-IR), quantitative insulin-sensitivity check index (QUICKI), and fasting glucose/insulin ratio (FGIR) were stronger ...